Alex Smith on ESPN's The John Keim Report: "Here's a Company Actually Trying to Do Something"

Former NFL quarterback and Oxeia board member Alex Smith joined ESPN's The John Keim Report to discuss his work with Oxeia, why concussion treatment hasn't changed in "a hundred years," and the cost to football as "superstars miss games every week."

After 16 years in the NFL experiencing persistent concussion symptoms firsthand, Alex joined Oxeia's mission to bring OXE103, which demonstrated an 85% responder rate versus 33% for standard care in Phase 2a trials, through Phase 2b trials toward FDA approval.

Join the mission to bring the first FDA-approved treatment for persistent concussion symptoms to market. Visit our campaign page on StartEngine .

This Reg CF offering is made available through StartEngine Primary LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.